An ongoing dialogue on HIV/AIDS, infectious diseases,
January 27th, 2010
No Vicriviroc — Yet
Apparently, Merck — taking over for Schering-Plough — will not seek approval for vicriviroc in treatment-experienced patients:
In two Phase III studies in this patient population, vicriviroc did not meet the primary efficacy endpoint. These studies enrolled a high percentage of patients who had three or more active drugs in their optimized background therapy regimen.
The report goes on to say that the results of these studies will be presented at CROI next month, and that other studies of vicriviroc in treatment-naive patients will continue.
Even though we don’t know the details yet, it’s understandable how this trial didn’t show any benefit for vicriviroc. With the “optimized background therapy” having 3 or more active drugs, how could it? We’re a long way from the TORO/T-20 days, when such “OBT” led to virologic suppression in < 10% of patients.
The control arms in these studies now just do too well. Progress!
Still, given the checkered history of this particular CCR5 antagonist — including a failed phase II study in treatment-naive patients and a possible signal of increased malignancies in another trial — the FDA approval for any indication might be a long hill to climb.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026 August 6, 2026Bundibugyo virus, a filovirus, is currently spreading in the Democratic Republic of Congo. This report presents early data on symptoms and illness severity as well as diagnostic challenges.
- Ebola at 50 — Lessons for Outbreak Response and Preparedness August 6, 2026An accurate history of Ebola begins with partnerships, including those between responders and the populations they serve. One of its key lessons is that equity must be integral to outbreak preparedness.
- Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines August 6, 2026The Bundibugyo virus outbreak in the DRC and Uganda has focused concern on potential countermeasures. Investigators assessed cross-reactive immune responses in serum obtained during previous Ebola vaccine trials.
- The Inequality–Pandemic Cycle — Rethinking Preparedness August 6, 2026Increasing pandemic frequency and increasing economic inequality are creating a self-reinforcing cycle. What’s needed is therefore a new, inequality-informed approach to pandemic preparedness.
- The Social Contract of Bundibugyo Ebola Isolation August 6, 2026The lack of vaccines and disease-specific therapeutics for Bundibugyo Ebola has dramatically affected the community’s perception of Ebola treatment centers. In this context, trust becomes critical.
- Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026 August 6, 2026